双功能化介孔二氧化硅纳米颗粒靶向治疗ER(+)乳腺癌的合成及体外分析

IF 4.2 4区 医学 Q2 CHEMISTRY, MEDICINAL
Garima Mann, Kanchan Chauhan, Anupriya Adhikari, Karla Juarez-Moreno, Nikhil Kumar, Shivani Daksh, Meganathan Thirumal, Anupama Datta
{"title":"双功能化介孔二氧化硅纳米颗粒靶向治疗ER(+)乳腺癌的合成及体外分析","authors":"Garima Mann,&nbsp;Kanchan Chauhan,&nbsp;Anupriya Adhikari,&nbsp;Karla Juarez-Moreno,&nbsp;Nikhil Kumar,&nbsp;Shivani Daksh,&nbsp;Meganathan Thirumal,&nbsp;Anupama Datta","doi":"10.1002/ddr.70138","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Mesoporous silica nanoparticles have been extensively utilized for targeted drug delivery; the drugs are encapsulated in the pores, while the surface can be modified to make the nanoparticles target-specific. The work presented here focuses on the development of multifunctional theranostic mesoporous silica nanoparticles with estrogen receptor-positive [ER(+)] breast cancer as the target. The surface of the nanoparticles was dually functionalized to make the nanoparticles target-specific using an estradiol derivative via a facile click reaction and to attach a <sup>99m</sup>Tc complexing agent (DTPA) for SPECT imaging. The size of the spherical nanoparticles was 80–110 nm, and the nanosystem was subjected to various physicochemical analysis techniques. Mesoporous nanoparticles were loaded with tamoxifen, an FDA-approved ER antagonist. Drug release at pH 5.8 was much more rapid than at physiological pH 7.4, a beneficial characteristic for controlled drug delivery at the tumor site. Cellular internalization and competitive binding studies indicated estradiol-mediated preferential uptake by MCF-7 cells. The nanocarrier exhibited good antiproliferative activity towards the ER(+) MCF 7 cells with a 92% decline in cellular viability in 48 h, whereas the cellular viability of the estrogen receptor-negative [ER(−)] MDA-MB-231 cells remained &gt; 60%. Thus, our results suggest a high theranostic potential of MSN-Est for breast cancer management.</p>\n </div>","PeriodicalId":11291,"journal":{"name":"Drug Development Research","volume":"86 5","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis and In Vitro Analysis of Dual-Functionalized Mesoporous Silica Nanoparticles for Targeted Theranosis of ER(+) Breast Cancer\",\"authors\":\"Garima Mann,&nbsp;Kanchan Chauhan,&nbsp;Anupriya Adhikari,&nbsp;Karla Juarez-Moreno,&nbsp;Nikhil Kumar,&nbsp;Shivani Daksh,&nbsp;Meganathan Thirumal,&nbsp;Anupama Datta\",\"doi\":\"10.1002/ddr.70138\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Mesoporous silica nanoparticles have been extensively utilized for targeted drug delivery; the drugs are encapsulated in the pores, while the surface can be modified to make the nanoparticles target-specific. The work presented here focuses on the development of multifunctional theranostic mesoporous silica nanoparticles with estrogen receptor-positive [ER(+)] breast cancer as the target. The surface of the nanoparticles was dually functionalized to make the nanoparticles target-specific using an estradiol derivative via a facile click reaction and to attach a <sup>99m</sup>Tc complexing agent (DTPA) for SPECT imaging. The size of the spherical nanoparticles was 80–110 nm, and the nanosystem was subjected to various physicochemical analysis techniques. Mesoporous nanoparticles were loaded with tamoxifen, an FDA-approved ER antagonist. Drug release at pH 5.8 was much more rapid than at physiological pH 7.4, a beneficial characteristic for controlled drug delivery at the tumor site. Cellular internalization and competitive binding studies indicated estradiol-mediated preferential uptake by MCF-7 cells. The nanocarrier exhibited good antiproliferative activity towards the ER(+) MCF 7 cells with a 92% decline in cellular viability in 48 h, whereas the cellular viability of the estrogen receptor-negative [ER(−)] MDA-MB-231 cells remained &gt; 60%. Thus, our results suggest a high theranostic potential of MSN-Est for breast cancer management.</p>\\n </div>\",\"PeriodicalId\":11291,\"journal\":{\"name\":\"Drug Development Research\",\"volume\":\"86 5\",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-08-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Development Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/ddr.70138\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development Research","FirstCategoryId":"3","ListUrlMain":"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/ddr.70138","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

介孔二氧化硅纳米颗粒已广泛用于靶向药物递送;药物被封装在孔隙中,而表面可以被修饰以使纳米颗粒具有靶向性。本文的工作重点是开发多功能治疗介孔二氧化硅纳米颗粒,以雌激素受体阳性[ER(+)]乳腺癌为目标。纳米颗粒的表面被双重功能化,通过简单的点击反应使用雌二醇衍生物使纳米颗粒具有靶向性,并附着99mTc络合剂(DTPA)用于SPECT成像。制备的球形纳米颗粒的粒径为80 ~ 110 nm,并对纳米体系进行了各种理化分析。介孔纳米颗粒装载了经fda批准的内质网拮抗剂他莫昔芬。pH值为5.8时的药物释放速度比生理pH值为7.4时快得多,这是控制药物在肿瘤部位传递的有利特性。细胞内化和竞争结合研究表明,雌二醇介导的MCF-7细胞优先摄取。纳米载体对ER(+) mcf7细胞表现出良好的抗增殖活性,48 h后细胞活力下降92%,而雌激素受体阴性[ER(−)]MDA-MB-231细胞的细胞活力保持60%。因此,我们的结果表明MSN-Est在乳腺癌治疗中具有很高的治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Synthesis and In Vitro Analysis of Dual-Functionalized Mesoporous Silica Nanoparticles for Targeted Theranosis of ER(+) Breast Cancer

Synthesis and In Vitro Analysis of Dual-Functionalized Mesoporous Silica Nanoparticles for Targeted Theranosis of ER(+) Breast Cancer

Synthesis and In Vitro Analysis of Dual-Functionalized Mesoporous Silica Nanoparticles for Targeted Theranosis of ER(+) Breast Cancer

Synthesis and In Vitro Analysis of Dual-Functionalized Mesoporous Silica Nanoparticles for Targeted Theranosis of ER(+) Breast Cancer

Mesoporous silica nanoparticles have been extensively utilized for targeted drug delivery; the drugs are encapsulated in the pores, while the surface can be modified to make the nanoparticles target-specific. The work presented here focuses on the development of multifunctional theranostic mesoporous silica nanoparticles with estrogen receptor-positive [ER(+)] breast cancer as the target. The surface of the nanoparticles was dually functionalized to make the nanoparticles target-specific using an estradiol derivative via a facile click reaction and to attach a 99mTc complexing agent (DTPA) for SPECT imaging. The size of the spherical nanoparticles was 80–110 nm, and the nanosystem was subjected to various physicochemical analysis techniques. Mesoporous nanoparticles were loaded with tamoxifen, an FDA-approved ER antagonist. Drug release at pH 5.8 was much more rapid than at physiological pH 7.4, a beneficial characteristic for controlled drug delivery at the tumor site. Cellular internalization and competitive binding studies indicated estradiol-mediated preferential uptake by MCF-7 cells. The nanocarrier exhibited good antiproliferative activity towards the ER(+) MCF 7 cells with a 92% decline in cellular viability in 48 h, whereas the cellular viability of the estrogen receptor-negative [ER(−)] MDA-MB-231 cells remained > 60%. Thus, our results suggest a high theranostic potential of MSN-Est for breast cancer management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.40
自引率
2.60%
发文量
104
审稿时长
6-12 weeks
期刊介绍: Drug Development Research focuses on research topics related to the discovery and development of new therapeutic entities. The journal publishes original research articles on medicinal chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, and drug delivery, formulation, and pharmacokinetics. The journal welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy, and regulatory issues involving the drug discovery and development process. In addition to full-length articles, Drug Development Research publishes Brief Reports on important and timely new research findings, as well as in-depth review articles. The journal also features periodic special thematic issues devoted to specific compound classes, new technologies, and broad aspects of drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信